Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BalanceD-HF
ChiCTR2500095453Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of balcinrenone and dapagliflozin in heart failure (HF) and chronic kidney disease (CKD) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Time to first composite cardiovascular endpoint. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500095453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095453.